Faculty profile

Kenneth Croitoru

ResearcherImmunologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Kenneth Croitoru

Researcher

Immunology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
42 publications in the last five years, latest in 2026.
Senior (last) author on 17 recent papers, a sign of leading a research group.
Principal investigator on 8 research grants (8 CIHR), most recently in 2025.
Supervised 8 trainees who won CIHR awards, most recently in 2019.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,616

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Health Geography Immigration Immune System Microbiome Nutrition Urban Environments Carbohydrate Colon Cancer

Latest papers

Tryptophan pathway metabotypes associate with disease activity and immune-metabolic dysfunction in inflammatory bowel disease.
medRxiv : the preprint server for health sciences · 2026
DUOX2-mediated gut barrier dysfunction: a preclinical mechanism in IBD pathogenesis?
Gut · 2026
Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials.
Gut · 2026 · senior author

All 84 publications

Latest funding

Therapeutic interventions to prevent colon cancer caused by pks+ E.coli
CIHR · 2025 · Principal investigator
Understanding the pro-inflammatory and protective potential of the Gut Microbiome in Developing Novel Therapeutic Approaches to Prevent Crohn's Disease
CIHR · 2023 · Nominated PI
$780,300
Defining the pre-inflammatory changes of gut microbiome, metabolome, and host proteome associated with the development of Crohn's disease in healthy first-degree relatives of Crohn's disease patients
CIHR · 2019 · Supervisor
$55,000

All 19 grants and awards

84 publications.

Tryptophan pathway metabotypes associate with disease activity and immune-metabolic dysfunction in inflammatory bowel disease.

Harris DMM, Bourgonje AR, Braadland PR, McShane C, Welz L, Waschina S, Ibing S, Tran F, Sands BE, Dubinsky M, Suarez-Farinas M, Argmann C, Ueland PM, McCann A, Detlie TE, Bengtson MB, Kristensen V, Franke A, Colombel JF, Rosenstiel P, Croitoru K, Sokol H, Turpin W, Hov JR, Høivik ML, Ungaro RC, Schreiber S, Aden K

medRxiv : the preprint server for health sciences2026

DOI: 10.64898/2026.05.03.26352309 PMID: 42145595

DUOX2-mediated gut barrier dysfunction: a preclinical mechanism in IBD pathogenesis?

Phi Dang C, Croitoru K, Turpin W

Gut2026

DOI: 10.1136/gutjnl-2025-335565 PMID: 40467103

Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials.

Turner D, Kenigsberg S, Focht G, Turpin W, Ledder O, Griffiths AM, Huynh HQ, Plotkin L, Aharoni-Frutkoff Y, El-Matary W, Otley AR, Avni-Biron I, Jacobson K, Panaccione R, Torres J, Lee SH, Croitoru K

Gut2026Senior author

DOI: 10.1136/gutjnl-2025-336368 PMID: 41381180

Prediction and Prevention of Inflammatory Bowel Disease: A Call to Action.

Lee SH, Lopes EW, Khalili H, Croitoru K, Colombel JF, Peter I, 2025 PROMISE Workshop participants

Gastroenterology2026

DOI: 10.1053/j.gastro.2025.09.042 PMID: 41410638

From preclinical phase of Crohn's disease to postoperative recurrence: shared mechanisms and potential interventions.

Chen R, Turpin W, Allez M, Silverberg MS, Croitoru K, Lee SH

Gut2026

DOI: 10.1136/gutjnl-2025-337981 PMID: 42209193

Defining preclinical stages of Crohn's disease by faecal calprotectin and other risk factors: response to letter.

Turner D, Kenigsberg S, Focht G, Croitoru K

Gut2026Senior author

DOI: 10.1136/gutjnl-2026-338188 PMID: 41633807

Real-World Outcomes of Upadacitinib vs Risankizumab Among Anti-Tumor Necrosis Factor-Exposed Patients With Crohn's Disease.

McShane C, Olivera PA, Candido K, Milgrom R, Borowski K, Kim J, Stempak J, Nguyen GC, Tandon P, Weizman AV, Croitoru K, Gallinger Z, Huang V, Targownik LE, Steinhart AH, Lee SH, Silverberg MS

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026

DOI: 10.1016/j.cgh.2026.06.005 PMID: 42297318

Vedolizumab treatment outcomes in early versus late Crohn's disease.

Chen R, Croitoru K, Lee SH

The lancet. Gastroenterology & hepatology2026

DOI: 10.1016/s2468-1253(25)00372-3 PMID: 41690317

β-Glucan and Inulin Estimated Intake Are Associated With Reduced Risk of Crohn's Disease, Improved Gut Barrier and Systemic Inflammation Markers, and Multi-Omic Signatures in a High-Risk Cohort

Xue M, McShane C, Kim J, Khorasaniha R, Leibovitzh H, Shao J, Chen R, Jeong S, Madsen KL, Griffiths AM

Gastroenterology20263 citations

DOI: 10.1053/j.gastro.2026.05.006

Serum IgG Response to a Conserved Domain of Commensal Flagellins Predicts Future Risk of Crohn’s Disease in First-Degree Relatives

Wu RY, Xue M, Zhao Q, Jeong S, Griffiths AM, Dieleman LA, Steinhart AH, Aumais G, Bressler B, Panaccione R

Clinical Gastroenterology and Hepatology20263 citationsSenior author

DOI: 10.1016/j.cgh.2025.12.006

Something wrong or missing on this profile? Suggest a correction

Kenneth Croitoru

Research

Latest papers

Latest funding

Tryptophan pathway metabotypes associate with disease activity and immune-metabolic dysfunction in inflammatory bowel disease.

DUOX2-mediated gut barrier dysfunction: a preclinical mechanism in IBD pathogenesis?

Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials.

Prediction and Prevention of Inflammatory Bowel Disease: A Call to Action.

From preclinical phase of Crohn's disease to postoperative recurrence: shared mechanisms and potential interventions.

Defining preclinical stages of Crohn's disease by faecal calprotectin and other risk factors: response to letter.

Real-World Outcomes of Upadacitinib vs Risankizumab Among Anti-Tumor Necrosis Factor-Exposed Patients With Crohn's Disease.

Vedolizumab treatment outcomes in early versus late Crohn's disease.

β-Glucan and Inulin Estimated Intake Are Associated With Reduced Risk of Crohn's Disease, Improved Gut Barrier and Systemic Inflammation Markers, and Multi-Omic Signatures in a High-Risk Cohort

Serum IgG Response to a Conserved Domain of Commensal Flagellins Predicts Future Risk of Crohn’s Disease in First-Degree Relatives

Frequent collaborators

Paul Moayyedi

Remo Panaccione

Wei Xu

Osvaldo Espin Garcia

John Kenneth Marshall

Michael Surette

Alain Bitton

Anthony Otley

David Mack

Sanjay Murthy

Osvaldo Espin Garcia

Anne Griffiths

Jennifer Jones

Konstantin Shestopaloff

Stephen Vanner

Karen Madsen

Teresa To

Astrid Guttmann

Thomas Walters

Alberto Martin

Kevan Jacobson

Geoffrey Nguyen

Brian Feagan

Gilaad Kaplan

Christoph Licht

Dhenuka Radhakrishnan

Jo Knight

Karen Madsen

Heather Armstrong

Vipul Jairath

Heather Armstrong

Shannon Dunn

Neeraj Narula

Elena Verdu

Premysl Bercik

Alberto Caminero Fernandez

Heather Galipeau

Paul Beck

Minna Woo